# QBitaLabs Partnership Strategy Playbook

**CONFIDENTIAL**

*Strategic Partnerships for Market Acceleration*

---

## Executive Summary

Strategic partnerships are critical to QBitaLabs' success. We operate at the intersection of multiple complex industries—quantum computing, pharmaceuticals, healthcare IT, and AI—requiring deep collaboration with established players while maintaining our independent value proposition.

### Partnership Goals

1. **Validate Technology**: Gain credibility through pharma partnerships
2. **Accelerate Distribution**: Leverage health IT channel partners
3. **Access Infrastructure**: Secure quantum hardware partnerships
4. **Generate Revenue**: Convert pilots to commercial relationships
5. **Enhance Capabilities**: Fill technology gaps through integration

---

## Partnership Categories

### Category 1: Pharmaceutical Partners (Revenue + Validation)

#### Strategic Rationale

- **Primary revenue source** ($500K-$2M per partnership annually)
- **Technology validation** for investor credibility
- **Data access** for model improvement
- **Regulatory pathway** guidance

#### Target Companies

| Tier | Companies | Deal Size | Timeline |
|------|-----------|-----------|----------|
| 1 | Pfizer, Roche, Novartis, J&J | $1-5M/year | 6-12 months |
| 2 | AstraZeneca, Merck, BMS, GSK | $500K-2M/year | 3-6 months |
| 3 | Gilead, Amgen, Lilly, Abbvie | $200K-1M/year | 3-6 months |

#### Engagement Model

**Phase 1: Innovation/R&D Pilot** (3-6 months)
- Funded pilot: $100K-$250K
- Specific use case: One target, one molecule class
- Success metrics: Accuracy, speed, cost reduction
- Team: 2-3 QBitaLabs scientists embedded

**Phase 2: Expanded Deployment** (6-12 months)
- Multi-target expansion
- Integration with existing pipelines
- $500K-$1M annual license
- Joint publication/case study

**Phase 3: Strategic Partnership** (12+ months)
- Enterprise license ($2M+/year)
- Exclusive access to new features
- Joint R&D programs
- Potential equity investment

#### Deal Structure Templates

**Option A: Pure SaaS**
```
Year 1: $250K license + $50K implementation
Year 2: $400K license
Year 3: $600K license + per-molecule fees
```

**Option B: Risk-Share**
```
Upfront: $100K
Success fee: $X per compound advancing to Phase 1
Royalty: 0.5% on approved drugs
```

**Option C: Joint Venture**
```
Co-investment in specific therapeutic area
Revenue share on joint discoveries
Exclusive license in defined field
```

#### Key Contacts & Entry Points

| Company | Entry Point | Warm Path |
|---------|-------------|-----------|
| Pfizer | Worldwide R&D Digital | [Advisor connection] |
| Roche | Pharma Partnering | JP Morgan Healthcare |
| Novartis | Data Science Hub | MIT quantum network |
| AstraZeneca | Open Innovation | Recent AI acquisitions team |

---

### Category 2: Health System Partners (Distribution + Data)

#### Strategic Rationale

- **Clinical validation** for Digital Twin product
- **Real-world data** for model training
- **Reference customers** for enterprise sales
- **Regulatory evidence** generation

#### Target Systems

| System | Size | Strategic Value |
|--------|------|-----------------|
| Kaiser Permanente | 12.6M members | Population health |
| Mayo Clinic | 1.3M patients/year | Clinical credibility |
| Cleveland Clinic | 7.5M visits/year | Cardiology expertise |
| Mass General Brigham | 2.6M patients | Boston ecosystem |
| UPMC | 4M members | Innovation culture |
| Intermountain | 2.5M patients | Value-based care |

#### Engagement Model

**Phase 1: Research Collaboration** (6-12 months)
- IRB-approved study
- Retrospective data analysis
- Publication in peer-reviewed journal
- No cost to health system

**Phase 2: Clinical Pilot** (12-18 months)
- Prospective study with clinical integration
- 50-100 patient pilot
- Workflow integration with EMR
- $50K-$100K pilot fee

**Phase 3: Enterprise Deployment** (18+ months)
- Full clinical deployment
- EMR integration (Epic, Cerner)
- $200K-$500K annual license
- Outcomes-based pricing optional

#### Partnership Pitch for Health Systems

**Value Proposition**:
- Reduce adverse events by 20%+ through better predictions
- Decrease length of stay with personalized protocols
- Improve patient outcomes with treatment optimization
- Generate research publications and grant opportunities

**Risk Mitigation**:
- HIPAA-compliant architecture
- De-identified data processing option
- No patient contact required for research phase
- All liability on QBitaLabs during pilot

---

### Category 3: Technology Partners (Infrastructure)

#### 3A: Quantum Hardware Partners

| Partner | Hardware | Value | Our Offer |
|---------|----------|-------|-----------|
| IBM | Superconducting | Largest qubit count | Healthcare showcase |
| IonQ | Trapped ion | Best fidelity | Life science vertical |
| Rigetti | Hybrid classical | AWS integration | Enterprise channel |
| Quantinuum | Trapped ion | Industrial focus | Pharma deployment |
| QuEra | Neutral atom | Optimization | Research partnership |

**Proposed Partnership Terms**:
- Discounted quantum computing credits
- Early access to new hardware
- Joint marketing and case studies
- Co-development of healthcare-specific algorithms

#### 3B: Cloud Partners

| Partner | Quantum Service | Strategic Value |
|---------|-----------------|-----------------|
| AWS | Amazon Braket | Enterprise customers |
| Microsoft | Azure Quantum | Healthcare IT |
| Google Cloud | Quantum AI | Research partnerships |

**Partnership Model**:
- ISV partnership for marketplace listing
- Co-sell arrangements with sales teams
- Technical integration support
- Credits for startup programs

#### 3C: Healthcare IT Partners

| Partner | Product | Integration Value |
|---------|---------|-------------------|
| Epic | EMR | 250+ health systems |
| Cerner | EMR | 200+ health systems |
| Veeva | Life science cloud | Pharma customers |
| Medidata | Clinical trials | Trial data access |

**Partnership Goals**:
- App Store listing in Epic/Cerner
- Data integration APIs
- Joint sales opportunities
- Certification programs

---

### Category 4: Academic & Research Partners

#### Strategic Rationale

- **Talent pipeline** for hiring
- **Research credibility** for publications
- **Grant funding** access
- **Advisory network** building

#### Target Institutions

| Institution | Department | Value |
|-------------|------------|-------|
| MIT | Quantum Information | Top talent, Boston hub |
| Stanford | Chemistry/Bio | West coast network |
| Caltech | Quantum Physics | Deep tech expertise |
| Harvard | Systems Biology | Medical applications |
| Cambridge | Quantum Computing | European expansion |
| ETH Zurich | Computational | European pharma |

#### Collaboration Models

**Sponsored Research**
- $100K-$500K annual funding
- Joint publications
- First right to license IP
- Student internship pipeline

**Visiting Scientist Program**
- 6-12 month placements
- Access to our platform for research
- Publication collaboration
- Potential full-time offers

**Consortium Membership**
- MIT Quantum Initiative
- Stanford HAI
- Broad Institute partnerships
- DOE National Labs

---

### Category 5: Government & Regulatory Partners

#### FDA Engagement Strategy

| Milestone | Timing | Purpose |
|-----------|--------|---------|
| Pre-submission meeting | Q2 2026 | Regulatory pathway clarity |
| Breakthrough designation | Q4 2026 | Expedited review |
| 510(k) submission | Q2 2027 | Diagnostic module |
| De novo classification | Q4 2027 | Novel digital twin |

**Regulatory Strategy**:
1. Start with lower-risk analytics products
2. Establish Software as Medical Device (SaMD) credibility
3. Build evidence base through clinical studies
4. Expand to higher-risk clinical decision support

#### Government Funding

| Agency | Program | Amount | Timeline |
|--------|---------|--------|----------|
| NIH | SBIR Phase II | $1.5M | Q2 2026 |
| DOE | Quantum Computing | $2M | Q3 2026 |
| DARPA | Bio-computing | $3M | Q4 2026 |
| NSF | AI Healthcare | $500K | Q1 2026 |

---

## Partnership Negotiation Playbook

### Red Lines (Non-Negotiable)

- [ ] We retain all core IP
- [ ] No exclusive licenses without substantial upfront payment
- [ ] Data usage rights for model improvement
- [ ] Right to publish (with partner review)
- [ ] Termination rights with reasonable notice

### Negotiable Terms

| Term | Preferred | Acceptable | Walk Away |
|------|-----------|------------|-----------|
| Exclusivity | Non-exclusive | Field-specific (18 mo) | Broad exclusive |
| IP ownership | 100% QBitaLabs | Joint development shared | Partner owns core |
| Payment terms | Net 30 | Net 60 | Net 90+ |
| Data rights | Full access | Aggregated/anonymized | No access |
| Liability cap | 1x contract value | 2x contract value | Unlimited |

### Deal Process

1. **Discovery Call** (30 min)
   - Understand their needs
   - Qualify opportunity
   - Schedule technical deep-dive

2. **Technical Deep Dive** (2 hours)
   - Demo platform
   - Discuss specific use case
   - Identify data requirements

3. **Proposal Presentation** (1 hour)
   - Custom proposal document
   - Pricing and terms
   - Implementation timeline

4. **Pilot Agreement** (2-4 weeks)
   - Negotiate pilot scope
   - Legal review
   - Sign pilot agreement

5. **Pilot Execution** (3-6 months)
   - Weekly status calls
   - Technical support
   - Success metrics tracking

6. **Commercial Conversion** (4-8 weeks)
   - Present results
   - Negotiate enterprise terms
   - Sign commercial agreement

---

## Partnership Team Structure

### Current (Stealth Phase)

| Role | Person | Focus |
|------|--------|-------|
| CEO | [Founder] | Pharma relationships |
| CTO | [Founder] | Technology partnerships |
| CSO | [Founder] | Academic partnerships |

### Post-Series A

| Role | Hire Timing | Focus |
|------|-------------|-------|
| VP Partnerships | Q1 2026 | Overall strategy |
| Director, Pharma | Q2 2026 | Pharma deals |
| Director, Health Systems | Q3 2026 | Hospital partnerships |
| Partner Manager x2 | Q4 2026 | Deal execution |

---

## Partner Success Metrics

### Tracking Dashboard

| Metric | Target | Current |
|--------|--------|---------|
| LOIs signed | 5 | 3 |
| Pilots active | 3 | 1 |
| Pilots converting | 80% | TBD |
| Partner NPS | 50+ | TBD |
| Partner-sourced revenue | 40% | 0% |

### Partner Health Score

| Score | Definition | Action |
|-------|------------|--------|
| 90-100 | Champion | Expand, reference |
| 70-89 | Healthy | Maintain, grow |
| 50-69 | At risk | Intervention |
| <50 | Churning | Executive escalation |

---

## Appendix: Partnership Collateral

### Required Materials

- [ ] Partner overview deck (10 slides)
- [ ] Technical integration guide
- [ ] Case study template
- [ ] ROI calculator
- [ ] Implementation timeline template
- [ ] SLA document
- [ ] Master partnership agreement template
- [ ] Data security whitepaper
- [ ] HIPAA compliance documentation

### Partner Portal (Future)

- Self-service demo environment
- Documentation and API reference
- Training materials
- Support ticket system
- Partner directory and community

---

*This playbook is a living document. Update quarterly based on market feedback and partnership learnings.*
